Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | $182.95M |
| Net Income (Most Recent Fiscal Year) | $-115.55M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.35 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.02 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -44.91% |
| Net Margin (Trailing 12 Months) | -44.91% |
| Return on Equity (Trailing 12 Months) | -39.72% |
| Return on Assets (Trailing 12 Months) | -25.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.57 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.21 |
| Inventory Turnover (Trailing 12 Months) | 6.32 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.87 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.64 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.73 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.01M |
| Free Float | 38.24M |
| Market Capitalization | $1.72B |
| Average Volume (Last 20 Days) | 0.50M |
| Beta (Past 60 Months) | 0.83 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.97% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |